SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The fireside chat session is scheduled for Monday, June 9, in Miami, FL, ...

Summary of Boundless Bio (BOLD) Update / Briefing May 27, 2025 Company Overview - **Company**: Boundless Bio (BOLD) - **Focus**: Development of therapies for oncogene amplified cancers, particularly through the study of extrachromosomal DNA (e cDNA) biology [5][6] Key Industry Insights - **Industry Context**: The biotechnology sector is facing challenges in securing funding and establishing differentiation due to a proliferation of competitor compounds [38] - **Market Considerations**: The company is prioritizing first-in-class drugs against innovative biological targets to maintain a competitive edge [38] Core Points and Arguments 1. **Portfolio Prioritization**: Boundless Bio has decided to discontinue all current arms of the BBI-355 clinical trial due to clinical observations and market considerations, shifting focus to a new trial arm evaluating BBI-355 in combination with BBI-825 [3][4] 2. **Workforce Reduction**: The company has streamlined operations, reducing its workforce by approximately 20 positions, representing about one-third of its staff, to extend its cash runway into the first half of 2028 [4][36] 3. **Development Candidates**: BBI-940 has been declared a development candidate for the novel kinesin oral degrader program, with an IND filing expected in the first half of 2026 [4][36] 4. **Clinical Findings**: BBI-355 has shown evidence of anti-tumor activity but has a narrow therapeutic index due to on-target hematologic toxicity, leading to the decision not to advance certain clinical arms [12][14] 5. **Combination Therapy Rationale**: The combination of BBI-355 and BBI-825 is believed to provide synergistic anti-tumor activity while minimizing hematologic toxicity, with plans to initiate clinical development in 2025 [28][29] Additional Important Content - **Scientific Basis**: The company has developed a proprietary SpyGlass platform to identify new targets in e cDNA biology, leading to the discovery of three druggable targets that may be synthetic lethal in oncogene amplified tumors [5][6] - **Clinical Strategy**: The combination of BBI-355 and BBI-825 is expected to leverage the unique mechanisms of both drugs, potentially overcoming the limitations observed when each is used independently [20][28] - **Preclinical Data**: BBI-940 has demonstrated potent anti-tumor activity in preclinical models, with favorable pharmacokinetics and oral bioavailability [33][34] - **Future Outlook**: The company is focused on achieving important clinical readout milestones and believes it is uniquely positioned with proprietary selective inhibitors [39][70] Financial Guidance - **Cash Runway**: The changes in operations and portfolio prioritization are expected to extend the company's cash runway into the first half of 2028, aligning with anticipated clinical readouts [36][37]

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to ...

Core Insights - Smirnoff launched its new flavor, Electric Guava, at a vibrant event called Calle Electric in Miami, showcasing a blend of cultural expression and music [1][2] - The event featured a surprise debut of a new track by DJs Coco & Breezy, enhancing the overall experience of the new flavor [2] - Electric Guava is designed for easy sipping, combining guava and ginger flavors, and is priced at $12.99 for a 750 ml bottle [3] Product Details - Electric Guava has a 25% alcohol by volume (ABV) and is available nationwide, with a limited supply encouraging consumers to purchase quickly [3][4] - The classic Spicy Tamarind flavor is also highlighted, priced similarly at $12.99 for a 750 ml bottle but with a higher ABV of 30% [4] - Smirnoff continues to innovate with its product offerings, including ready-to-serve beverages and limited editions that cater to evolving consumer tastes [10] Brand Strategy - The introduction of Electric Guava reflects Smirnoff's commitment to celebrating cultural flavors, particularly those rooted in Hispanic culture [4] - The brand emphasizes diversity and inclusion, aiming to create enjoyable experiences for all consumers aged 21 and above [8] - Smirnoff has a long history of adapting to consumer preferences, having launched various iconic products since its inception in 1864 [7][10]

Boundless Bio, Inc. (BOLD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to ____________ Commission File Number: 001-41989 BOUNDLESS BIO, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 83-075 ...

Exhibit 99.1 Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 BBI-355, a novel, oral, potent CHK1 inhibitor designed to target repli ...

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to del ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-41989 BOUNDLESS BIO, INC. (Exact name of registrant as specified in its charter) Delaware 83-0751369 (State or othe ...

Financial Performance - Boundless Bio reported a cash position of $152.1 million as of December 31, 2024, an increase from $120.8 million in 2023[9] - The net loss for Q4 2024 was $16.4 million, compared to a net loss of $12.1 million in Q4 2023, and the full year net loss for 2024 totaled $65.4 million, up from $49.4 million in 2023[9] - The total operating expenses for the full year 2024 were $73.3 million, compared to $54.8 million in 2023[13] Research and Development - Research and Development (R&D) expenses for Q4 2024 were $13.3 million, up from $10.4 million in Q4 2023, and total R&D expenses for the full year 2024 were $55.3 million compared to $42.6 million in 2023[9] - Boundless Bio is advancing the BBI-355 Phase 1/2 POTENTIATE trial, with preliminary proof-of-concept data expected in the second half of 2025[1][2] - The company expects to report preliminary clinical proof-of-concept safety and antitumor activity data for BBI-355 in the second half of 2025[3] - Boundless Bio's ecDNA-directed therapeutic candidate, BBI-355, is being evaluated in a clinical trial targeting oncogene amplified cancers, which affect 14 to 17% of cancer patients[6] General and Administrative Expenses - General and Administrative (G&A) expenses for Q4 2024 were $5.0 million, compared to $3.4 million in Q4 2023, with total G&A expenses for the full year 2024 at $18.0 million versus $12.2 million in 2023[9] Leadership Changes - Boundless Bio appointed Robert Doebele, M.D., Ph.D., as Chief Medical Officer in February 2025, enhancing its leadership in oncology[4] Future Development Plans - The company is on track to nominate a development candidate for its novel Kinesin program by mid-2025, with an IND submission anticipated in the first half of 2026[1][2]